| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/01/2013 | EP2586768A1 Hydroxy acid compound of substituted phenyl ester, preparation method and medical use thereof |
| 05/01/2013 | EP2586464A1 Tolvaptan solid dispersion and its preparation method |
| 05/01/2013 | EP2586463A1 Pharmaceutical multimeric particles, and manufacturing method for same |
| 05/01/2013 | EP2586462A1 Prophylactic or ameliorating agent for genetic diseases |
| 05/01/2013 | EP2586453A1 Tumor growth controlling method targeting galactosylceramide expression factor-1 |
| 05/01/2013 | EP2586448A1 Skin properties improving agent for oral administration |
| 05/01/2013 | EP2586447A1 Heterochain aliphatic poly-n-oxide copolymers and vaccinating agents and drugs based thereon |
| 05/01/2013 | EP2586446A1 Use of 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide for the treatment of infectious salmon anaemia (isa) in salmonids |
| 05/01/2013 | EP2586445A1 Methods of facilitating cell survival using neurotrophin mimetics |
| 05/01/2013 | EP2586444A1 Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition |
| 05/01/2013 | EP2586443A1 Antitumor agent using compounds having kinase inhibitory effect in combination |
| 05/01/2013 | EP2586442A1 Sustained-release therapeutic agent for hypertension and renal dysfunction |
| 05/01/2013 | EP2586441A1 Combination of egcg or methylated egcg and a pde inhibitor |
| 05/01/2013 | EP2586440A2 Methods for preventing and treating microbial infections by modulating transcription factors |
| 05/01/2013 | EP2586439A1 Combination therapy with a compound acting as a platelet ADP receptor inhibitor |
| 05/01/2013 | EP2586438A1 Compound useful for preventing cognitive deficit disorders in a new born from HIV-seropositive pregnant female who is in treatment with azidothymidine |
| 05/01/2013 | EP2586437A1 Composition containing at least one nutritive, at least one disinfecting or decontaminating, and/or at least one protease-inhibiting active compound and/or active compound complex |
| 05/01/2013 | EP2586436A1 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| 05/01/2013 | EP2586435A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| 05/01/2013 | EP2586434A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| 05/01/2013 | EP2586433A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| 05/01/2013 | EP2586432A2 Co-crystals of Tramadol and NSAIDs like Coxibs |
| 05/01/2013 | EP2586430A2 Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved |
| 05/01/2013 | EP2586427A2 Balsalazide formulations and manufacture thereof |
| 05/01/2013 | EP2586426A1 Carboxyvinyl polymer-containing nanoparticle suspensions |
| 05/01/2013 | EP2586425A1 Preparing method of allicin injection and low temperature continuous stirring ultrafiltration device thereof |
| 05/01/2013 | EP2586424A1 New pharmaceutical combinations |
| 05/01/2013 | EP2585828A2 Methods of treating patients with immune-related diseases |
| 05/01/2013 | EP2585596A2 Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
| 05/01/2013 | EP2585594A1 Double stranded rna compounds to rhoa and use thereof |
| 05/01/2013 | EP2585470A2 Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity |
| 05/01/2013 | EP2585469A1 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors |
| 05/01/2013 | EP2585468A1 Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| 05/01/2013 | EP2585467A1 Pyrazolo [1, 5 -a]pyrimidines as antiviral agents |
| 05/01/2013 | EP2585466A1 Polymorphs of osi-906 |
| 05/01/2013 | EP2585465A1 Benzotriazolodiazepine compounds inhibitors of bromodomains |
| 05/01/2013 | EP2585463A1 Beta carboline derivatives useful in the treatment of proliferative disorders |
| 05/01/2013 | EP2585462A1 Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| 05/01/2013 | EP2585461A1 2,4- diaryl - substituted [1,8]naphthyridines as kinase inhibitors for use against cancer |
| 05/01/2013 | EP2585460A1 Quinolizidine and indolizidine derivatives |
| 05/01/2013 | EP2585459A1 Alkaloid aminoester derivatives and medicinal compositions thereof |
| 05/01/2013 | EP2585458A1 Alkaloid aminoester derivatives and medicinal composition thereof |
| 05/01/2013 | EP2585457A1 Alkaloid aminoester derivatives and medicinal composition thereof |
| 05/01/2013 | EP2585456A1 Amido-tropane derivatives |
| 05/01/2013 | EP2585455A2 Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
| 05/01/2013 | EP2585454A1 Heteroaryl compounds and compositions as protein kinase inhibitors |
| 05/01/2013 | EP2585450A1 Salts and polymorphs of dexrabeprazole |
| 05/01/2013 | EP2585448A1 Compounds and methods for the treatment or prevention of flavivirus infections |
| 05/01/2013 | EP2585447A2 Compounds and methods for the treatment or prevention of flavivirus infections |
| 05/01/2013 | EP2585446A1 Compounds having trpv1 antagonistic activity and uses thereof |
| 05/01/2013 | EP2585445A2 Polymorphs of an active pharmaceutical ingredient |
| 05/01/2013 | EP2585444A1 Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| 05/01/2013 | EP2585440A1 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia |
| 05/01/2013 | EP2585439A1 Heterocyclic compounds, their preparation and their therapeutic application |
| 05/01/2013 | EP2585437A2 Thioacetate compounds, compositions and methods of use |
| 05/01/2013 | EP2585435A1 6,7-dihydro-5h-benzo[7]annulene derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and the use thereof for production of medicaments |
| 05/01/2013 | EP2585161A1 Medical device for self-administration of patients with acute coronary events |
| 05/01/2013 | EP2585109A2 Compositions and methods for preventing and treating organ injury and/or dysfunction |
| 05/01/2013 | EP2585101A1 Diabetes therapy |
| 05/01/2013 | EP2585088A1 Composition for improving sexual wellness |
| 05/01/2013 | EP2585080A1 Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings |
| 05/01/2013 | EP2585079A1 Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery |
| 05/01/2013 | EP2585078A1 Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery |
| 05/01/2013 | EP2585077A1 Agent for suppressing the formation of abnormal skin cells caused by exposure to light |
| 05/01/2013 | EP2585076A1 Dialysis precursor composition |
| 05/01/2013 | EP2585075A2 Methods of treatment for esophageal inflammation |
| 05/01/2013 | EP2585074A1 Use of an estrogen derivative for the manufacture of pharmaceutical compositions useful for the treatment and/or prevention of psychiatric diseases and for the treatment and prevention of said diseases |
| 05/01/2013 | EP2585073A1 Antiviral compounds |
| 05/01/2013 | EP2585072A1 Niacin mimetics, and methods of use thereof |
| 05/01/2013 | EP2585071A1 Pharmaceutical composition for use in the treatment of glaucoma |
| 05/01/2013 | EP2585070A1 Use of 1h-quinazoline-2,4-diones |
| 05/01/2013 | EP2585069A1 Prokineticin 1 receptor antagonists for the treatment of pain |
| 05/01/2013 | EP2585068A1 Prokineticin 1 receptor antagonists for the treatment of pain |
| 05/01/2013 | EP2585067A1 Compound for the treatment of enteroviruses |
| 05/01/2013 | EP2585066A2 Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| 05/01/2013 | EP2585065A1 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
| 05/01/2013 | EP2585064A1 C5ar antagonists |
| 05/01/2013 | EP2585063A1 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone |
| 05/01/2013 | EP2585062A1 Injectable formulation of a macrocyclic lactone and levamisole |
| 05/01/2013 | EP2585061A2 Treatment of blood cancer |
| 05/01/2013 | EP2585060A1 Stimulating immune response |
| 05/01/2013 | EP2585059A1 Use of dibenzofuranone derivatives to inhibit kinases |
| 05/01/2013 | EP2585058A2 Prevention of proteomic and genomic damage by dicarbonyl substrates of glo 1 |
| 05/01/2013 | EP2585057A1 Methods of treatment using sterculic acid |
| 05/01/2013 | EP2585056A2 Composition and method of treating lipid encapsulated virus infections |
| 05/01/2013 | EP2585055A1 Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| 05/01/2013 | EP2585054A1 Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| 05/01/2013 | EP2585052A2 Controlled release compositions with reduced food effect |
| 05/01/2013 | EP2585051A2 Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| 05/01/2013 | EP2585050A1 Silodosin-cyclodextrin inclusion compounds |
| 05/01/2013 | EP2585049A1 Neramexane multiple unit dosage form |
| 05/01/2013 | EP2585048A1 Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| 05/01/2013 | EP2585047A1 Dry powder formulation comprising an antimuscarinic drug |
| 05/01/2013 | EP2585045A2 Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations |
| 05/01/2013 | EP2585043A2 A bioactive dose containing a material for modulating ph of a bodily fluid |
| 05/01/2013 | EP2585040A1 Compositions and methods for enhancing reduction of spore-forming microorganism |
| 05/01/2013 | EP2585039A2 Dialysis precursor composition |
| 05/01/2013 | EP2585038A1 Pharmaceutical composition comprising midazolam |
| 05/01/2013 | EP2585037A1 Topical ophthalmic suspensions containing tobramycin and dexamethasone |
| 05/01/2013 | EP2585024A1 Once-a-month method of contraception |